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Abstract: Artificial nutrition, including enteral (EN) and parenteral (PN) nutrition, is indicated
whenever adequate oral nutrition fails to sufficiently supply the necessary nutrients to the body. It is
a convenient, efficacious, safe, and well-tolerated form of clinical nutrition in the hospital and home
setting. EN is administered via nasogastric tube or ostomies while PN usually requires a central venous
access for administration, straight into the blood stream. The infused nutrients can then be taken up
directly by the different organs. PN is targeted as a single daily portion formulated as an oil-in-water
emulsion providing the necessary substrates for the catabolic and anabolic metabolism including
macro- and micronutrients and fluids. PN has a complex pharmaceutical composition—all-in-one
admixture—and its compounding or ready-to-use preparation. The use of PN is more challenging and
more expensive compare to the use of EN, commercially available as ready-to-use formulations. EN
and concomitant medication is highly challenging. Upon incorrect handling and administration, PN
is associated with potentially severe or even fatal complications, mostly relating to the central venous
access (e.g., catheter-related sepsis) or to a metabolic intolerance (e.g., hyperglycemia, refeeding
syndrome) because of inappropriate administration. A correct order of admixing, correct dosing, and
administration of the artificial is crucial for safety and efficacy; clinical and biochemical monitoring of
the patient and treatment regimen adaption are necessary. The high number of reactive solutes allow
only limited stability of a ready-to-use PN admixture. The potential for numerous incompatibilities
and interactions renders PN admixtures generally unsuitable as drug vehicle. Laboratory compatibility
and stability testing and pharmaceutical expertise are a prerequisite to define the PN composition
including nutrients or even drugs admixed to define the appropriate and individualized nutrition and
medication regimen. The aim of this narrative review is to present the actual state-of-the-art to deliver
best quality artificial nutrition with special regard on pharmaceutical aspects such as instabilities,
incompatibilities, and concomitant co-medication.
Keywords: parenteral nutrition; enteral nutrition; artificial nutrition; all-in-one parenteral admixture;
compatibility; stability; pharmaceutical expertise; drug admixing; drug administration
1. Introduction
Enteral nutrition (EN) is used whenever the gastrointestinal tract is functioning and when oral
access is impaired (e.g., chewing and/or swallowing issues). In patients with partial or total intestinal
failure, nutrients may not or not be sufficiently absorbed from the intestine. Hence, parenteral nutrition
(PN) has to be administered as a formulation, containing the necessary substrates, ready to be used in
the intermediate metabolism. Intestinal failure may result from an extensive surgical bowel resection
or a disease leading to reduced function of the intestine and/or impairment of motility, digestive or
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absorptive capacity (e.g., mesenteric infarction, laparoschisis, Morbus Hirschsprung). Table 1 shows
recently published data from Pironi et al. regarding epidemiology of intestinal failure in 3239 patients
across the world [1]. PN allows quantity- and quality-wise a full or partial nutritional support and
can guarantee survival and good quality of life. EN and PN are the two forms of artificial nutrition,
developed and introduced in the 1960s. EN and PN, or their combination, require an adapted and
individualized nutrition regimen respecting the specific condition and requirements of the patient.
Nowadays and in contrast to the early beginnings, EN and PN are mostly based on physico–chemically
fully defined, balanced and stable products, manufactured in industry. While EN products can
be delivered as stable ready-to-use formulations, total or partial PN has to be compounded or
prepared ready-to-use for administration compliant with pharmaceutical good manufacturing practice
(GMP) requirements. The available industrial PN premixes contain stable nutritional components
mechanically separated from each other in chambers with breakable sealing. Upon ready-to-use
preparation as all-in-one (AiO) admixture in a convenient, single container and for single line daily
PN treatment, the sealing is mechanically broken and the content manually shaken. For safety and
tolerance of administration of the usually hypertonic PN admixtures showing an osmolality exceeding
2000 mosm/kg, an inserted/implanted central intravenous access is required [2]. Consequently, PN and
its prerequisites are more challenging, more expensive, and more prone for complications compared to
EN. Nevertheless, a well-indicated PN according to existing guidelines shows good efficacy and safety
in patients, also in long lasting home PN and if assisted by a nutrition support team (NST) [3–8].
Table 1. Epidemiologic data from 3239 patients with chronic intestinal failure in countries around the
world, from Pironi et al. [1].
Type of Chronic Intestinal Failure Underlying Disease
Benign chronic intestinal failure
(n = 2919, 90.1%)
Crohn’s disease (22.4%)
Mesenteric ischemia (17.7%)
Surgical complications (15.8%)
Primary chronic intestinal pseudo-obstruction (9.7%)
Post-radiation enteritis (7.3%)
Others (21.3%, with <3% each-one)
Not reported (5.9%)
Malignant chronic intestinal failure
(n = 320, 9.9%)
Type of active cancer not specified (62%)
Gastrointestinal cancer (28%)
Extra-abdominal cancer (10%)
Concurrent enteritis due to radio- or chemotherapy (5%)
Peritoneal carcinomatosis (12%)
Databases such as PubMed and Cochrane were searched for guidelines, recommendations and
registries, using filters for human studies in English only, and excluding children, as well as homepages
from national and international nursing and nutritional societies. The aim of this narrative review is to
present the actual state-of-the-art for artificial nutrition delivery with special regard on pharmaceutical
aspects. This review aims to provide nutritionists dealing with artificial nutrition knowledge to
deliver best quality PN, understanding of the concept and benefits of the AiO, and the pharmaceutical
challenges of artificial nutrition (instabilities and incompatibilities, drug admixture).
2. Accesses for Artificial Nutrition
PN should be initiated at the latest after five to seven days of insufficient oral and/or enteral
feeding. This may be initiated even earlier in case of severe malnutrition [5]. Preoperative PN and also
EN have been for example been shown to improve surgical outcome in patients affected by Crohn’s
disease undergoing abdominal surgery [9,10]. The beneficial value of supplemental PN in critically
ill patients has also been demonstrated in recent prospective studies [11]. EN may be administered
via nasogastric tubes, nasojejunal tubes or percutaneous gastrostomy/jejunostomy (endoscopic or
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radiologic), Witzel fistulas or fine needle catheter jejunostomy, depending on the anticipated duration
of the EN therapy and of the indication. The need for a central venous access for PN is obvious
when for example calculating the individual daily requirements for electrolytes, which have to be
contained in an AiO PN admixture. These alone increase the tonicity by more than 600–800 mosmol/kg,
which is the maximal value for a peripherally administered intravenous infusion [5]. In long-term
PN, tunneled subclavian or jugular catheters (e.g., Hickman catheters), implanted port systems or
peripherally inserted central venous catheter (PICC) are used [6]. For short period of supplemental
PN, the administration of peripheral PN admixtures through peripheral venous catheter is possible.
Peripheral PN may be indicated for short-term use or as a supplement typically to maintain a previously
well-nourished, patient or to serve as a bridge to centrally administered infusions or until adequate
enteral feedings can be established [12,13]. The risk of microbial contamination and following growth
is greater with peripheral PN than with PN, mainly due to the lower osmolarity in peripheral PN [14].
Moreover, the risk of phlebitis and extravasation is high and causes catheter removal [15].
3. Handling of Feeding Tubes and Catheters
The handling of feeding tubes is much less demanding than the catheter handling, as it does not
require asepsis. It however largely depends on the type of tube. Regular dressing changes and slights
moves of the tubes are however mandatory.
To minimize PN-associated complications, the appropriate central intravenous device has to
be selected, placed, and inserted by a trained surgical team with experience. Together with good
and regularly trained catheter handling, these are the two most important factors to keep the main
intravenous access related complications in PN low. A rigorous aseptic technique is required for the
manipulation and care of the catheters and the connections [2]. Blood drawing including aspiration
through the central venous catheter has to be avoided. Suited trainings for patients and caregivers to
learn the defined rules and best practices are essential and must be documented and evaluated [16].
Such education includes aseptic handling of the PN bag, of catheters, and its connections including
also a rigorous handwashing procedure. Alcoholic chlorhexidine (0.5–2%) is recommended for skin
disinfection; there are possible disinfectant alternatives in case of contraindications [2]. When a port
system is used for PN, the giving set must be changed daily and in addition, the gripper needle has to
be changed every three to seven days according to accepted standards. Evidence-based policies also
apply for dressings of the exit sites [2]. The rinsing and plugging of the catheter with defined solutions
are of critical importance and saline (0.9%) is the standard solution to be used. Heparin, initially
recommended for port system rinsing, is still often used despite lacking appropriate compatibility
documentation. Bozetti et al. showed a significant increase of catheter-related complication using
heparin rinse compared to saline in HPN patients [17]. A recent Cochrane update analysis comparing
saline against heparin for intermittent catheter locking in adults showed no evidence for a heparin
benefit, as known from previous studies in children [18]. Heparin is prone to incompatibility reactions
with many PN components, e.g., lipids, potentially leading to occlusion and/or infection of catheters.
The use of heparin to rinse catheters lacks evidence regarding its effectiveness in reducing blood
clotting. Moreover, it is prone to incompatibilities with lipids and emulsifiers from the PN admixtures.
Even short and at low dose, heparin exposure in an intravenous line has shown emulsion cracking [19].
As a consequence of the cracking, lipid deposits form in catheters increasing risk for infectious
complication and obstruction, possibly leading to catheter removal [6]. The potential risk to induce
heparin hypersensitivity has also to be considered. In the actual PN guidelines, heparin is not more
recommended for catheter rinsing and plugging [2,6,18]. A lock solution with taurolidine, a synthetic
antimicrobial agent, might be considered in PN patients with repeated catheter-associated infections
but should not be routinely used [20]. Other antibiotic lock solutions (vancomycin, gentamycin) are
also used although the evidence for a preventing effect is low. Ethanol locks may be considered for
secondary prevention in some cases. The use of in-line filters is not supported by the necessary evidence,
similarly to heparin use or antibiotic prophylaxis [2]. Therefore, these methods are not considered as
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universal and compulsory preventive measures for all PN patients [5–7]. In-line filters may be used to
(1) filter out precipitates or particles (reduce risk of embolism), (2) prevent pathogenic microorganisms
to enter the bloodstream (reduce risk of infection), (3) hinder air to be infused into blood circulation
(air embolization). In-line filters may however also create new problems [21]. They may themselves
release particles or cause adsorption of nutrients or drugs reducing their systemic availability. In-line
filters may thus also potentially be blocked and impair the PN administration. A fatality has even
been associated with the use of in-line filters, as calcium phosphate precipitation occurred in the
filtered admixture after warming up in the line [22]. There are no general recommendations for the
use of in-line filters. German guidelines on PN settle beneficial effects of in-line filters in specific risk
patient populations (e.g., children and immune-compromised patients) [23]. The ASPEN however
recommends the use of 0.22 micron filter for lipid-free PN admixtures, and 1.2 micron filter for AiO
admixtures [24]. The filter should be placed as close to the patient as possible and should be exchanged
with each new PN container, as well as the administration set.
4. Complications of Enteral Nutrition
EN is generally efficient, safe and well tolerated. Small bore tubes made of more flexible materials,
careful nursing and therapy monitoring contribute to decrease the complication rates. Risk factors for
complications are among others neurological impairment, anatomical abnormalities, and advanced
age [25]. Systematic antibiotic therapy before tube placement to prevent infectious complications
(wounds and systemic infect) is controversially discussed. There is however good evidence for
at-risk patients (e.g., immunocompromised patients) and placement of gastroscopic accesses [25].
Administration of a single dose of broad spectrum antibiotic half an hour before EN device placement
has been shown to reduce peristomal infects by 22%. Complications rates vary according to the type of
access, e.g., 0.3–15% for nasoenteric tubes, 1–4% for major and 13–40% for minor complications for
endoscopic accesses. Complications rates are very low for surgical needle catheter jejeunostomies.
4.1. Gastrointestinal Complications
Gastrointestinal complications are frequent with enteral feeding [26]. Diarrhea may be the most
common one, probably caused by adaption of the intestine after fasting period, by antibiotic therapy,
or administration of too cold solutions. Delivery sites and rates influence may also influence the
occurrence of diarrhea. Misplacement (too low) may be a further cause of diarrhea. Obstipation may
also occur with enteral feeding solutions containing low or no dietary fibers, due to dehydration,
immobility, or as a side effect of opiate therapy.
Nausea and vomiting may be due to tube dislocation, too fast administration or administration of
too high volume. It may also be caused by the underlying disease or the related treatments, or due to
medication containing sugar substitutes. Delayed gastric emptying and subsequent feeling of fullness
are risk factor for aspiration and may also cause vomiting [25].
Reflux esophagitis and early dumping are further complications of EN.
4.2. Mechanical Complications
Feeding tubes may be misplaced, dislocate, or cause perforation (trachea or gastrointestinal tract),
and nasal/gastrointestinal bleeding. Further, feeding tubes may be obstructed. Obstruction may be
prevented by sufficient and consequent rinsing procedures, and by avoiding drug administration
(as far as possible). There are various possibilities to re-open a tube, from warm water rinsing to
rinsing with pancreatic enzymes and bicarbonate solutions. Feeding tubes may also cause irritation,
and consecutive changes in the oral mucosa. Leaks or buried bumper syndrome may occur with PEG
devices [25].
Aspiration is a rare complication (1–4%), causing fever and possibly pneumonia [25]. It may
be silent or manifest with symptoms such as tachypnoea, tachycardia, and wheezing. Aspiration is
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however a great issue in critically ill patients [26]. It may be prevented elevating the head by 30–45◦
when lying [25].
4.3. Infectious Complications
Different infectious complications may occur during the EN therapy, such as pneumonia (arising
from aspiration pneumonia), sinusitis, or bacterial contamination of the nutritional solution [26]. Some
complications are related to the device, e.g., wound infection at the entry site with PEG devices and
peritonitis with gastroenterostomies. Infections mostly require tube change/removal [25].
4.4. Metabolic Complication
The metabolic complications of the enteral nutrition are similar to the one of parenteral nutrition
(e.g., the refeeding syndrome described in Section 5.3.1) but with much lower incidence and severity [25].
5. Complications of Parenteral Nutrition
5.1. Mechanical Complications
Catheters may sometimes dislocate or occlude, mainly due to incorrect manipulations. Reasons for
catheter occlusions are manifold: PN admixture instabilities, incompatibilities with rinsing solutions
and/or with other intravenous solutes administered through the catheter, etc. Taking blood samples
through the central venous access must be prohibited since it is almost impossible to completely clear
the line and the device afterwards. Moreover, blood samples from catheters often provide erroneous
results because of residues of the PN in the catheters with high electrolyte or lipid concentrations.
Blood clots may form and eventually mechanically occlude the catheter, being a possible origin of
microbial colonization. Occluded catheters may be rinsed with saline solutions (10–20 mL) in a first step,
applying slight pressure. If this is not successful, acidic or alkaline solutions may be applied according
to defined procedures [2]. Reopening of occluded catheters is however discussed very controversially
by the experts. It can be dangerous since clots may be microbially colonized. Blood stream infection
may consecutively occur. Lipid deposits may be eliminated with ethanol or diluted sodium hydroxide.
Thrombolytics are administered to eliminate an assumed blood clot [5,6]. Administration of PN with
infusion pumps also helps to prevent catheter occlusions since the flow rate is kept constant [7].
5.2. Infectious Complications
In the beginning of PN history, infections and sepsis were frequent (affecting up to 40% of
the patients) and thus a limitation to PN use [8]. By reducing the number of manipulations
(e.g., AiO admixture administration), the incidence of catheter sepsis radically dropped (Table 1).
Catheter-related sepsis occur at rates of 0.5–1 per catheter year in hospitals inpatients and 0.1–0.5 per
catheter year in patients on home PN [5]. Gram-positive microbes (from the skin) are the mostly
encountered microorganisms identified [2,27]. Catheter exit site-related or bloodstream infections are
predominant complications and are associated with increased morbidity and mortality rates. Moreover,
infectious complications contribute substantially to PN costs, causing additional hospitalizations and
catheter removals.
5.3. Metabolic Complications
5.3.1. Refeeding Syndrome
The refeeding syndrome is a potentially life-threatening metabolic condition occurring in seriously
malnourished patients or in patients recovering from severe catabolic diseases (e.g., sepsis, diabetic
ketoacidosis) after start of a nutritional therapy. From a pathophysiological point of view, refeeding
syndrome is an exaggerated response of the malnourished catabolic body to a nutritional therapy,
indeed to anabolism [28,29]. Refeeding syndrome is characterized by severe electrolyte shifts (mainly
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hypophosphatemia, hypomagnesemia, and hypokalemia), vitamin deficiency (mainly thiamine), fluid
overload and salt retention leading to organ dysfunction including cardiac arrhythmias up to death.
Symptoms such as heart failure, peripheral edema and neurologic disorders can occur. The refeeding
syndrome is most likely to appear within the first 72 h after initiation of the nutritional therapy. A risk
stratification of patients before prior to start a nutritional intervention is recommended and can then
by adapted according to the risk category [28,29]. Full energy requirements are targeted within five to
ten days after initiation of the nutritional therapy depending on the risk category, starting at a low
energy rate (5–15 kcal/kg/day) and increasing stepwise. Fluid management and sodium restriction
may be necessary in patients belonging to higher risk categories. Thiamine (vitamin B1) has to be
administrated as a 200–300 mg dose daily for three days, 30 min before the initiation of nutritional
support. Finally, provision of trace elements and vitamins in the single and double recommended daily
amounts of micronutrients, respectively, are recommended. Intensive clinical monitoring is mandatory
to detect early signs of refeeding syndrome, such as organ failure and fluid overload. It should include
vital signs, hydration status, and determinations of serum electrolyte levels.
5.3.2. Hyperglycemia
Hyperglycemia is another early and frequent complication affecting up to 50% of the patients upon
PN initiation. Appropriate and initially frequent glycaemia testing is mandatory, since hyperglycemia
has been linked with increased morbidity and mortality, especially in critically ill patients [30].
The targeted blood glucose level lies between 7.8 and 10.0 mM, (normoglycemia: 4.4–8.1 mM;
80–145 mg/100 mL) [31]. Insulin administration, optimally pump-assisted and in parallel to PN, may
be necessary to control glycaemia (there is a dedicated specific article on this topic in this special
issue [30]).
5.3.3. Liver-Associated Complications
Liver-associated PN complications are seen in up to 40% of the patients, especially in those with
short bowl with less than 150 cm of remaining small intestine and in absence of colon (Table 2) [2].
In case of occurring liver-associated PN complications (e.g., hypertriglyceridemia, cholelithiasis, and
cholestasis), it is recommended to administer PN formulations with reduced triglyceride (TG) content
and a better fatty acids (FA) mix (e.g., by a higher monounsaturated FA (MUFA) content or an increased
Ω-3 to Ω-6 ratio of the polyunsaturated FA (PUFA)) [2].
Table 2. Catheter- and parenteral nutrition (PN)-related complications [2].
Type Rates Measures Per Catheter Year (95% Confidence Interval)
Catheter sepsis 0.34 (0.32–0.37)
Catheter occlusion 0.07 (0.06–0.08)
Central vein thrombosis 0.03 (0.02–0.03)
Liver/biliary issues
Mild 0.42 (0.27–0.63)
Severe 0.02 (0.01–0.06)
Metabolic bone disease 0.05 (0.01–0.15)
5.3.4. Thrombosis
Central venous thrombosis is a common issue in PN patients with central venous access (up to
50% of PN patients) associated with high morbidity and mortality rates (Table 2). The localization is
mostly proximal to the catheter. The frequency of thrombosis is linked to the experience and skills of
the catheter insertion team as well as to the diameter of the catheter; small bore central venous catheters
are therefore recommended. Low dose oral anticoagulants may be used in high-risk patients [6].
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6. The Role of the Pharmacist and Specificities of Pharmaceutical Management
NSTs have multi-professional composition consisting of at least a physician, a specialized nurse,
a dietician and a pharmacist, skilled to manage PN, and to deliver best nutritional support [16].
Pharmacists within the NST have an important role to play in selecting, preparing and instructing
on the safe handling of nutritional products, especially PN. They have however also a clear role in
optimizing medication for patients with EN (BN Group). Pharmacists provide medicinal products, care,
and when necessary education and training related to artificial nutrition to the other NST members,
to patients and their caregivers. Pharmacists are in charge for the logistic of the products and of their
quality assurance. They check the drug and nutrients prescriptions from a pharmaceutical point of
view, advising on the most effective and safe administration of drugs in order to prevent interactions
and incompatibilities, in EN (administration via feeding tube) as well as in PN (admixture) [32].
Pharmacists are also in charge of the documentation and clarification of drug related adverse events,
to increase treatment safety. Most patients on artificial nutrition also require drug treatment for their
underlying diseases. This further complicates the overall treatment regimen aiming in given cases to
combine the parenteral administration of nutrients and drugs, e.g., as the indication for (home) PN
is extended to malignant chronic diseases or severe functional deficiency, often requiring additional
complex medication in parallel to the artificial nutrition. This is a complicated endeavor, which needs a
careful check of compatibility primarily respecting correct and suited dosing over time of both nutrition
and medication to ensure safe and efficacious treatment requesting pharmaceutical skills [6,8,33]. Drug
admixing issues are one of the main tasks of the pharmacist within the NST, who has to face and
assess PN- and drug-related problems from the pharmaceutical perspective [32]. The pharmacist also
contributes to define an appropriate nutritional and medical care plan, to avoid medication errors,
and finally keeps responsibility that the right patient gets the right products administered in the right
way [5,6,34].
7. Components of Artificial Nutrition
Standard commercial nutritional solutions for enteral use contain between 1 (isocaloric) and
2 kcal/mL (hypercaloric), with 15–20% proteins, 25–30% fats, and 50–60% carbohydrate, which
represents a suitable macronutrients distribution for most patients. They may contain dietary fibers or
not. Macromolecular and low-molecular weight solutions are available depending on the functionality
of the gastrointestinal tract. Additionally, metabolically adapted solutions (e.g., high protein, low
electrolyte content for kidney failure patients) or immunomodulating solutions (containing e.g.,
arginine or glutamine) are available. Organic amino acids (AA; protein), glucose (carbohydrate),
different TG of FA (fat), and inorganic/organic electrolytes/nutrients together with water are the small
molecular components of a PN [2]. Micronutrients, vitamins and trace elements have mostly to be
added for a total PN as they are not necessarily included in industrial multi-chamber bags. Energy
requirement in adults is 25–30 kcal/kg/day given as a mix of the most important universal fuel glucose
and high caloric lipids. In contrast to EN, the AA content of PN is not calculated as energy as AA
are primarily intended building components for protein synthesis which has to be considered when
assessing the balance of EN and PN. The basic protein need in adults is 0.8–1 g/kg/day increasing to
1.2–1.5 g/kg/day in malnourished patients and even higher in special situations (e.g., 2.5 g/kg/day in
burned patients or children). The energy need mainly depends the resting energy expenditure and on
disease activity and severity (possibly increasing the requirements by 50%).
7.1. Amino Acids
In a severe catabolic state, glucose may be produced from AA over the formation of acetyl-CoA
and through the Krebs cycle or over the pyruvate gluconeogenesis pathway (for glucose-dependent
organs, e.g., brain), yielding in 1 g AA = 4 kcal. The protein (AA) breakdown may be estimated through
the urine output, since nitrogen from the AA is eliminated as urea. One gram of urea contained in
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the urine matches 7.34 g of AA (0.47 g nitrogen). This calculation can be used for an intake-output
estimate e.g., in well-monitored critically ill patients.
From the 21 AA, there are seven essential (isoleucine, leucine, lysine, methionine, phenylalanine,
threonine, tryptophan, and valine) and four conditionally essential AA (histidine, tyrosine,
cytosine, glutamine, and taurine). When AA show additional pharmacological effects, the term
pharmaconutrition is used. This applies to glutamine, although the evidence for effectiveness is
still debated. Commercial AA solutions for PN are traditionally crystalline solutions of L-AA (10%),
despite differences between the manufacturers in the conditionally essential AA content (mainly
glycine) [2]. AA in solutions are filled in airtight containers and protected by the antioxidant nitrogen
gas, since oxygen oxidation (ambient air) is very likely to occur. AA and glucose put together in vitro
can react and undergo Maillard reaction, which may influence their availability. Thus, a yellow to
brownish colored product is then visible upon exposition to ambient conditions as e.g., beyond 24–48 h
hanging time of ready-to-use AiO admixtures. The AA content in a daily dose of AiO PN admixture
reaches 1.2–1.5 g/kg (100–150 g AA). In order to reverse catabolism (AA breakdown), AA should
be administered together with fat/carbohydrates (mainly glucose). The suggested caloric intake is
20–27 kcal/g AA [5,7]. Optional admixtures of pharmaconutrients (e.g., 0.2 g glutamine/kg/day in
trauma or burned patients) are dosed additionally to the necessary AA amount of the PN regimen and
have to be taken into account in the nutrient balance.
7.2. Glucose
Around 66% of the body’s energy fuel is normally provided by carbohydrates (1 g = 4 kcal),
mainly by glucose, the primary and physiological energy substrate in the intermediate metabolism.
It is prone to oxidative degradation when in solution. Some organs (e.g., blood and brain) fully depend
on glucose for meet their energy requirements. Hence, mechanism such as gluconeogenesis ensures
a minimal necessary glucose production (37 g/day) when external supply is insufficient or lacking
and the restricted glycogen stores (150–300 g) empty [2]. Highly concentrated, hypertonic glucose
solution is used to restrict the volume of an AiO PN admixtures and primarily contributing to their
hyperosmolarity. Maximal infusion rate in adults is 3–6 g glucose/kg over 24 h. This rate is limiting the
maximal infusion rate since the rate of glucose oxidation to pyruvate/acetyl-CoA/Krebs cycle in adults
is limited to 5–7 mg/kg/min [2]. The level of blood glucose during PN has to be kept <10 mM and has
to be regularly monitored, especially in the beginning of PN [31,35].
7.3. Lipids
Commercial intravenous lipid oil-in-water emulsions contain 100–200 g lipid/L [2]. The TG used
are composed of different (PU)FA. The oil-in-water emulsion is stabilized with soya or egg yolk lecithin
(12 g/L), a phosphatidylcholine with a negative surface charge resulting from the phosphate groups [36].
The surface charge is negative from the anionic phosphate moiety of the emulsifier at the surface of
the oil droplets. This negative zeta potential keeps the emulsified oil droplets separated. The anionic
charge of the phosphate lecithin moiety at the surface is critical for destabilizing incompatibilities, e.g.,
with (mainly polyvalent) cations. Intravenous lipid emulsions are nearly isotonic and contribute to
decrease the osmolarity of an AiO PN admixture, e.g., in PN administered peripherally. Important to
know, about 15 mmol phosphate are delivered from the emulsifier per liter of a commercial parenteral
lipid emulsion [2]. TG are important energy fuels providing 9 kcal/g through the beta-oxidation of FA
and the subsequent acetyl-CoA metabolism. Different FA types are contained in intravenous lipid
emulsions, depending on the lipid sources. Nowadays, “structured lipids” are mostly being used,
like SMOF lipids containing 30% soybean FA, 30% MCT, 25% olive oil FA, and 15% fish oil FA. Lipid
emulsions dose in PN reaches 0.5–1.0 g/kg/day to cover about 33% of the patients’ energy requirements.
Lipids may be used to a higher extend in critically ill patients (up to 50%) to avoid insulin resistance
issues [2]. Since they are partially essential FA, PUFAs must be included in AiO PN admixtures
in the required doses. Ω-3 PUFAs like EPA (eicosatetraenoic acid) or DHA (docosahexaenoic acid)
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show anti-inflammatory effects through the synthesis of prostaglandins and leukotrienes and may be
considered as pharmaconutrients. On the contrary,Ω-6 PUFAs shows pro-inflammatory effects forming
arachidonic acid over the prostaglandins and leukotrienes pathways. Ω-9 MUFA have no action on
these pathways and thus are neutral. Middle chain triglycerides (MCT) only contain non-essential
saturated FA. They can be oxidized to produce energy directly in the mitochondria in absence of
carnitine unlike long chain PUFAs. PUFAs are highly prone to peroxidation; resulting in toxic reaction
products (e.g., radicals and aldehydes) contributing to the systemic inflammation and the oxidative
stress of patients. Light and oxygen protection for storage and transport are therefore important
to prevent peroxidation [37,38]. The oil droplet characteristics and distribution in the oil-in-water
emulsion is a critical parameter. It should mimic the physiologic chylomicrons or lipoproteins with a
critical upper diameter size of 5 µm correlating to a small blood vessel diameter. Larger droplets may
eventually cause lipid embolism, while degradation products of lipid peroxidation may as radicals
free cause DNA damages and contribute to inflammation [2,16].
7.4. Fluids and Electrolytes
Sufficient water and electrolytes doses have also to be provided by a nutrition regimen. Additional
oral fluid or infusions to PN may be needed to reach the basic fluid requirements in adults of 30–40
mL/kg/day, but also to cover abnormal losses such as fever, vomiting, diarrhea, or stoma losses, burns
and severe wounds [39]. The combination compatible amounts of (di- and trivalent) cations and
anions in AiO admixture preventing instabilities e.g., by harmful precipitations of salts or deteriorated
oil-in-water characteristics by interactions with the emulsifier is a pharmaceutical challenge.
7.5. Micronutrients
Daily administration of EN > 1500 mL covers the daily recommended micronutrients intake. Since
most micronutrients are hydrophilic and body stores are limited, total PN must also cover vitamins and
trace elements requirements from its initiation. Trace elements (polyvalent cations) show relevant and
concentration-dependent physicochemical interactions e.g., with the oil-in-water emulsifier; they may
also be catalyzers of chemical degradation processes (e.g., oxidation) [2]. This may become an issue
since vitamins and trace elements are both infused into AiO PN bags. As an example, iron or copper
catalyze the oxidation of the ascorbic acid (vitamin C), which then degrades within minutes. From
an evidence-based standpoint, trace elements and vitamins should be administrated separately, e.g.,
trace elements admixed to the AA portion, and vitamins only given at the end of a PN administration
limiting the exposure time of combined physical presence in the admixture [4–6].
7.6. The All-In-One Concept as the Pharmaceutical Formulation of Choice
PN is a complex, meta-stable, high quality pharmaceutical formulation defined by the
pharmacopoeia. In presence of lipid, it represents an oil-in-water emulsion and contains various,
partially ionized, reactive solutes, prone for physicochemical interactions. PN is highly concentrated
(hypertonic) and its components are often close to their solubility limits as the volume is restricted [32].
A PN regimen has to be practicable and convenient, efficacious and safe, also upon long term use (home
PN). Central venous access is needed for the administration and aseptic techniques are needed during
ready-to-use preparation of industrial premixes or tailor-made compounding since PN has to be sterile
and pyrogen-free [6]. Correct conditions for transport and storage and finally for the administration
and hanging time are required to provide the right and ready to be metabolized amount of nutrients to
fulfil the nutritional needs and to prevent and/or correct metabolic/physicochemical disturbances.
The PN composition and if needed its individualization has always been and is a challenge to
ensure safety and optimal efficiency. The increased knowledge of disease and stress metabolism has
contributed to diminish complications and to increase tolerance of PN [2]. Historically, PN started
from the difficult to handle multi bottle to a convenient single container AiO system delivered as a
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ready-to-use complete daily portion enabling individualized, more physiologic and well-tolerated 24 h
or cyclic co-administration of the nutrients (mostly overnight) [4,40].
Total PN admixtures and regimens contain over 50 individual solutes, mostly representing
reactive species (Figure 1). This explains the stability issues and the important potential for
physicochemical interactions such as degradation of components, generation of toxic products
like reactive aldehydes from fatty acid degradation or harming precipitates formed from interacting
electrolytes [2]. Additionally, a critically reduced homogeneity of the oil-in-water fat emulsion
with eventual oiling out may cause serious adverse effects. The control and avoidance of microbial
contamination are key issues to reduce infectious complications. Nowadays, pharmaceutical GMP
rules are established and require for example to work in a laminar airflow bench for aseptic
compounding/ready-to-use preparation. There are guidelines for correct labelling, storage, hanging
time (24 h after ready to use preparation), transport and storage (2–8 ◦C) of AiO PN admixtures [4].
The combined admixing of potentially interacting or even incompatible microelements like trace
elements with vitamins are still debated. Trace elements can catalyze oxidation and radical formation
of e.g., vitamins [4,6] or of PUFA [37]. An acceptable, appropriately documented compromise has to
be defined for the appropriate quality of the AiO admixture administered and the provision of the
necessary amount of nutrients. Individualized compounding or ready-to-use preparation of a complete
PN results in an AiO admixture, which cannot to be sterilized anymore by an established heating
procedure [2]. Hence, in many countries, ready-to-use AiO PN has to be prepared according to the GMP
rules and regulatory authorization is needed. There are however countries where extemporaneous
parenteral nutrition preparations do not need any specific regulatory authorizations. The industrial
approach with serial manufacturing targeted stable and storable PN products to overcome the stability
issues of individually compounded AiO PN admixtures. This resulted in the development of different
forms of special multi-chamber bags, separating the lipid emulsion, the AA and the glucose solutions
from each other by mechanically separated chambers or compartments [2]. The bags materials
are innovative multi-layered foils allowing vapor sterilization of the filled and sealed chambers
representing AiO PN premixes which are with the additional air-tight wrapping including oxygen
absorbing materials stable up to years as the main chemical destabilization by oxidative degradation of
the nutrients is almost eliminated [40]. Ready-to-use preparation of these commercial AiO PN premixes
includes mechanical breaking of the chamber sealing and manual shaking of the combined content
still in a closed container envelop thus in aseptic conditions. Admixing of other needed components
(electrolytes, micronutrients, or other intravenous supplements according to need and compatibility)
into individual chambers require suited stability data, and defined and validated admixing procedures.
The major part of PN adult patients can be treated with commercialized products. Therefore, PN
treatment is sensibly facilitated. Nevertheless, individual PN compounding remains needed in selected
patients, especially in children or neonates with their body growth requirements but also adults with
home PN and/or after mesenteric infarction. However, such a service is available only in particular
and experienced hospital pharmacies or compounding centers often also challenged for an appropriate
logistic [2]. The evidence is still lacking whether an individualized tailor-made PN regime provides
better outcome in neonates, acute critically ill patients or for patients in the home setting compared
to a standardized commercial AiO PN. The debate concerning the individual energy, macro- and
micronutrient requirements is still ongoing [41,42].
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Stability defines that he admixture components do not degrade in excess (e.g., <10%).
Compatibility defines that t ese co pon nts do ot physico–chemically interact with each other
over a defined time. Stability and compatibility must last from compounding to delivery, up to
the declared expiry date, and the administration under defined conditions. Both aspects are critical
for the quality, efficacy and safety f t e product [43] Th re are many physicochemical interactions
occurring: instabilities (emulsion), solubility (precipitations), photo-induced (catalytic reactions),
thermic reactions, material interactions (sorption, permeation), and chemical reactions (oxidation,
reduction, hydrolysis, polymerization, deca box lation, com lexation, lipid peroxidation, Maillard
reaction, etc.). A decrease in pH below 5.0 seriously compromises lipid emulsion stability. The first
visible sign of decreased homogeneity of the oil-in-water emulsion is creaming (appearance of a white
upper layer) [21]. Crea ing is reversibl by gent mechanical shaking and occurs without a significant
change in the mean particle size nor the particle size distribution. Such AiO PN admixture can be
safely administered to the patient. The coalescence is the next deterioration step, which is not anymore
reversible. La ger lipid droplets increasingly form over time and may be visible at the surface [21].
Coalescence may be measured by a light extinction method or validated microscopic analysis [44,45]
Such emulsions should no more be administered to patients as they may induce adverse effects (e.g.,
inflammatio fr phagocytized fat globules, or embolism) [46]. The ultimat step f the on-going
droplet enlargement is the emulsion breaking or cracking, where large fat globules separate from the
dispersed oil-in-water phase [21]. Administration of such formulations is prohibited. These interactions
occur between the components present in AiO PN admixture. They can become critical upon admixing
and administration of higher amounts of electrolytes leading to precipitates when disrespecting the
solubility product, which is influenced by specific conditions in the PN admixture (volume, pH,
temperature, chelating components like AA for cations) [2]. Administration of parenterals containing
precipitates may cause small vessels occlusion and consecutive organ damages, and may even become
fatal when such precipitates are delivered e.g., into the lung [2]. Precipitates may as well occlude central
venous catheter [2,16]. Critical concentrations of divalent cations (mainly Mg2+ and Ca2+) in presence
of inorganic phosphate lead to precipitation of insoluble phosphate salts. High requirements of such
electrolytes exist in neonates but also in adults are incompatible in the amount needed since compatible
concentrations for AiO PN admixture are overreached [2]. Such incompatibilities constitute medication
errors and are preventable by careful expert proof and choice of appropriate formulations and dose
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of an individual AiO admixture by the pharmacist [34]. Replacing inorganic salts by organic ones
may sometimes also prevent such insolubilities like organic (not hydrolyzed) glycerophosphates [6].
As a rule of thumb, monovalent (mainly Na+ and K+) and divalent (mainly Mg2+ and Ca2+) cations
concentrations in AiO admixtures should not exceed 130 mmol/L and 8 mmol/L, respectively (relative
ratio of about 15 between mono- and divalent cations) [21,47].
Compatibility and stability of calcium and phosphate in PN admixtures depend on many
factors, such as concentrations, pH, nature of the salts (inorganic or organic), presence/concentration
of electrolytes, composition and concentration of the AA solution, lipid emulsion, mixing order,
temperature, storage, and hanging time since admixing [21]. High concentrations of calcium and
inorganic sodium or potassium phosphate (mono- or dibasic) salts show a greater risk of precipitation
at room temperature due to the variation in solubility products at different pH (factor 60). The more
acidic pH of peripheral PN admixtures (due to lower AA and/or glucose concentrations and increased
lipid concentration) compared to central AiO PN admixtures (high osmolarity) also reduces calcium
phosphate solubility [21]. Low infusion rates and room temperature, e.g., in PN admixtures for
neonates, contribute to increase the risk of precipitation, eventually occurring during administration
and consecutively causing severe organ damages, especially in the lungs. Calcium phosphate
precipitation may also occur when iron dextran or bicarbonate are added to PN or infused through
the same line without sufficient previous line rinsing [21]. Concentrations of organic calcium (e.g.,
gluconate) should not exceed 2.5 mmol/L in adult formulations with low osmolarity. Phosphate
concentration (mono- and dibasic sodium phosphate salts) should not exceed 15 mmol/L [48]. Organic
phosphate salts (e.g., glucoso-1-phosphate or glycerol phosphate) should be used in case of increased
needs for calcium and phosphate (e.g., children or neonates). However, organic salts are prone to
hydrolysis, possibly releasing highly incompatible inorganic phosphate [49].
Another critical reaction partner is the lipid emulsifier lecithin, a negatively charged natural, large
molecular AiO PN component, important to control and stabilize the lipid droplet size, and their size
distribution in intravenous formulations. Eventually, the stability of the emulsion is most decisive
for the overall stability and safety of an individual AiO PN admixture. Polyvalent cations may react
and neutralize the negatively charged phosphate moieties of lecithin at the lipid droplet surface (zeta
potential) which is intended to hinder (reversible) aggregation of oil droplets (oil droplet agglomerates).
Over time, agglomerates can further develop to irreversible oil droplet coalescence. The enlarged oil
droplets (>5 µm diameter) are able to obstruct small blood vesicles (lipid embolism) [2]. Breaking apart
of the emulsion and oiling out can occur, which has to be avoided strictly, whereas the initial oil droplet
formation is potentially visible at the surface of an AiO PN admixture [2]. Their detection is challenging,
and microscopic analysis might be a better approach [50]. Even though this microscopic technique is
promising, it is not a recommended method to date. The United States pharmacopoeia recommends
measuring the volume-weighted percent of fat droplets greater than 5 µm or PFAT5, must not exceed
0.05% of the total fat (PFAT5) [51] This measurement is usually performed by the manufacturer in
an accredited laboratory and not in the daily analytical routine of hospital pharmacies [21]. Even
small amounts of trace elements (µM concentration) or locally higher concentration upon admixing
of components in a wrong order may influence the emulsion stability and safety. Solubilizers for
lipophilic drugs used as vehicles in parenteral drug formulations when admixed or in contact with
AiO PN may rise the emulsion stability. This negatively affects the lipid clearance in the body of
administered TG from the AiO PN admixture since oil-in-water emulsion becomes meta-stable and
thus resist to greater extent to enzymatic plasma lipid clearance [4].
8.1. Vitamin Stability
Some vitamins (e.g., vitamins A, B1, B2, B6, C and K) are chemically unstable and are easily
oxidized with air and light. Vitamin A as a lipophilic compound may also interact with the PN
container or the infusion set (absorption and/or adsorption). Vitamin B1 and B6 are unstable in presence
of oxygen and in direct interaction with trace elements. Vitamin C is also easily degraded to oxalic
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acid reacting with calcium to form calcium oxalate precipitate [52]. Clinical deficiencies may occur due
to such instabilities. Undesired degradation products (e.g., oxalate) may also be infused. Interactions
between labile vitamins and PN components are manifold and therefore difficult to extrapolate in
theory. Vitamins may only be added to PN AiO admixtures if specific and sufficient stability data
are available. In best practice, vitamins should be added to AiO just before or at the very end of
the PN administration [21]. This in order to reduce interaction time and eventual time-dependent
degradation. Fat-soluble vitamins (A, D, E, K) can be added to lipid-containing AiO admixtures or into
lipid infusions. They may be administered weekly or monthly (vitamin K) according to their storage
in the body. Vitamins may be protected from light exposure and degradation by lipid emulsions,
however, they are themselves prone to peroxidation. Light protection of AiO admixture containers
containing vitamins is thus generally recommended during storage and administration [21]. Adding
combined admixture of trace elements and vitamins hides high incompatibility potential (e.g., iron and
vitamin C) and is therefore not recommended without specific stability data. Commercial multivitamin
preparations can be safely administered as separate infusion or even as a slow bolus injection between
daily administration of PN portions [53].
8.2. Trace Elements Compatibility
Copper cysteinate, iron phosphate, and formation of insoluble elemental selenium from selenite
reduction with vitamin C are the best-known compatibility issues with trace elements [54]. Commercial
trace elements solutions show very acidic pH (pH 2), which is critical for lipid stability. Emulsion
stability and peroxidation are also negatively influenced by polyvalent cations (e.g., iron, copper,
selenium, chrome and zinc) [38,49,55,56]. TG hydrolysis or admixing of trace elements may cause
critical pH drop (below pH 5) hampering the emulsion stability. Trace elements should therefore never
be added directly to lipid emulsion neither upon compounding nor in a multi-chamber bag. The pH of
parenteral products may vary between manufacturers, making it difficult to extrapolate data from one
brand to another. AA due to their pH buffering capacity may positively contribute to lipid emulsion
stability. AA also have the ability to complex polyvalent cations like electrolytes or trace elements
(chelation) avoiding bridging between negatively charged lipid droplets. During compounding or
admixing, electrolytes and/or trace elements should therefore be added into the AA solution.
9. Artificial Nutrition and Drug Admixture
9.1. Drug Administration via Feeding Tube
Whenever drug administration occurs via a feeding tube, basic pharmaceutical questions arise
to implement safe and efficient therapy: Can the tablet be crushed, or the capsule opened? How
should a therapy plan ultimately be put into practice? Drug delivery via a feeding tube is an
interprofessional challenge and requires special expertise from all involved stakeholders. Medical,
nursing and pharmaceutical aspects have to be considered. The versatility of orally available drug
formulations is large and includes specific forms with modified drug release or protective tablet coatings.
Interactions between drugs, nutrients, and the human organism can lead to physicochemical reactions
and pharmacological changes affecting treatment’s efficacy and safety [57]. The prevention and
handling of such interactions requires pharmaceutical advice and expertise. Incorrect administration
of EN and/or medication due to improper handling must be considered as avoidable medication
errors. While various international guidelines have been developed for the nutrition of patients,
recommendations for the administration of drugs via feeding tubes are primarily based on empirical
values [58]. Information on the accessibility of drugs to medications are not provided as standard
information and therefore available only by means of extensive literature research. In 2012, Prohaska
et al. found that information on the administration of antiretroviral drugs via feeding tube was
only reported in 63% of the cases [59]. Significant problems may occur if drugs galenic is changed,
e.g., when a tablet is crushed instead of swallowed. Fatalities have for example been reported after
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a retarded nifedipine preparation was repeatedly unduly crushed, and administered via feeding
tube [60]. Enteral tubes are challenging for the caregivers, both during the hospital stay and after
discharge. Resulting ambiguity in the care responsibility can endanger patient safety. Nowadays, tubes
made of polyurethane or silicone should be used for EN. These materials guarantee a minimal foreign
body sensation and good compatibility over a longer lying time. Polyvinyl chloride (PVC) should
be used only for short periods because of the risk of pressure necrosis due to the washing out of the
plasticizers [61,62]. Interactions between the tube material and the active ingredients of EN are common.
PVC may for example retain relevant levels of carbamazepine, clonazepam, diazepam, phenytoin or
tacrolimus, leading to treatment failure [63,64]. The position of the tube tip has a decisive influence on
the release and absorption of active ingredients (pH stomach = 1–2, pH duodenum/jejunum = 7–8).
Acid-sensitive drugs are destroyed in the acidic stomach environment. If a drug with an enteric coating
is crushed and administered via a gastric tube, this leads to a loss of effect, since the drug is early
degraded by the gastric acid. It is recommended to avoid administering medication through a jejunal
or duodenal tube. In the case of jejunal feeding tube placement, the total amount of fluid used in
drug administration should thus not exceed 50 mL. A time gap of 30 min should be kept between the
individual bolus doses or the next application; otherwise, it can lead to diarrhea. It should further be
taken into account that the tube tip does not have to be the site of the active ingredient intake, and that
the passage time in the gastrointestinal tract differs significantly from the oral intake. Consequently,
administration of drugs via feeding tube may result in a lower effectiveness or higher risk of side effects
compared to the oral route. Blood/urine levels of drugs with narrow therapeutic range administered
via a feeding tube should be regularly checked.
9.1.1. Administration of Drugs via Feeding Tube
From a methodical point of view, drug administration via feeding tube is challenging and offers
the possibility of interprofessional medication review [65]. This is ideally be done before the final
medication prescription, ensuring a safe and efficient administration. In the course of a visit on the
ward or in the nursing home, the pharmacist clarify with the physician whether the patient really needs
all prescribed drugs in his current situation. Any deprescribing relieves the patient and nursing staff,
and reduces complications. Decision for the administration of drug via feeding tube is supported in a
structured way as shown in Figure 2. The oral route should be preferred for the drug administration.
The patient’s ability to swallow has to be evaluated, and regularly promoted, as it may also depend on
the form of the day. Depending on the patient’s existing ability to swallow, solid dosage forms are
replaced by sublingual, liquid, mouth-melting, or transdermal forms. If the patient can swallow liquids,
medications should be offered in liquid form or as dispersible tablets (physiological route and less
complication potential than via tube). Medicines in liquid dosage form are moreover uncomplicated to
give over the tube than solid forms. Numerous interactions and reactions involving drug products,
nutrients, and tube devices exist despite the use of solid drug formulation (lower reactivity compared
to a dissolved drug delivery system).
Rectal, transdermal, nasal, sublingual or parenteral drug administration should be considered
as alternatives to drug application via feeding tube [66]. If no alternative medication is available,
an individualized formulation from the pharmacy may be considered. The tube system itself is equally
crucial to further assessment. A PEG is more suitable for drug administration than a transnasal or
a fine needle catheterized jejunostomy tube because of its brevity and width. The diameter and the
location of the tip of the tube are just as important. The osmolality of enteral nutrition is on average
300 mosmol/kg and must not exceed 500–600 mosmol/kg. The stomach tolerates osmolality of up
to 1000 mosmol/kg. Liquids with higher osmolality lead to diarrhea (due to a high volume of fluid
and electrolyte that cannot be absorbed in the small intestine), nausea, flatulence (due to delayed
gastric emptying), or vomiting. To prevent osmotic diarrhea or vomiting, drug formulations have to
be diluted with water to isotonic or slightly hypertonic (<400–500 mosmol/kg) solutions to be given
through the feeding tube. Even stricter isotonicity is required in case of small intestine tubes, due to
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the lack of dilution processes in the mouth, esophagus and stomach. Since the intestine, in contrast
to the stomach has no storage function, no liquid amounts of more than 50 mL should be given as a
bolus directly into the intestine. This significantly restricts the administration of several drugs with
according tube position.
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9.1.2. Safety Issues in the Administration of Dr gs via Tube
The preparation and administration of carcinogenic, mutagenic drugs or drugs toxic to
reproductio , so-called CMR drugs requir special attention. Thus, the r spective hazard risk
handling with cytostatics, anti-infectives/virustatics, hormones, and immunosuppressants must be
individually assessed. Work must then be carried out by trained staff, with the necessary protective
measures ( .g., gloves, dust mask, protective googles). Patients’ relatives an c regivers must be made
aware of the relative risk potential. Pregnant or breastfeeding women have to be relieved of such
activities. In addition, patients, relatives and caregivers must be informed about safer alternatives
dosage forms s liquid dosag forms for example carry less risk than tablets that have to be divided or
crushed. Open handling of CMR substances should always be avoided. Pharmacies having dedicated
facilities may provide CMR drugs as capsules or pre-filled syringes to minimize drug exposure. The
increasing number of oral cancer therapies on the drug market will lead to increased handling questions
in the outpatient care.
9.2. Drug Admixture to PN
Extrapolation of AiO PN admixtures stability data from the literature is rarely possible because of
the high number and concentration variabilities of components in an individual PN nutrition regimen
(Table 3). This is even more complicated in case of drug admixing. The multitude and the concentration
dependence of interactions create a multifactorial system not to be assessed by theoretical calculations
only. Generation of pharmaceutical stability data may therefore be required for specific cases for
documentation and reliability purposes. Sensitive and validated laboratory methods are available in
tertiary care hospitals, which may be useful for components of an AiO PN admixtures and concomitant
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therapy but have to be adapted for the specific in vitro investigation. Such evaluation tools may help
to assess the possibility to admix a specific item into a defined AiO PN composition or to check an
individual nutrient and/or drug interaction upon request from the clinic in a reasonable and relative
short time period [2]. Light microscopy may for example be applied to assess oil-in-water (oil droplet
sizing) emulsions. Even though the admixing of drugs to AiO PN admixtures is not recommended,
it may be needed in some cases. Compatibility and stability assessment of such combinations may
be performed by means of defined drug analytic methods for quantification, adapted from blood
plasma or serum to PN matrix [6,50]. Simple test methods have to be elaborated and validated to
be used for stability and compatibility assessment of individual admixes to AiO PN regimens upon
request [2,16,50].
Table 3. Advices to the possible drug admixture to AiO PN admixture.
Advice Not to Admix
• lipophilic drugs with solubilizes such as cremophors,
tweens, etc.
• drugs with rapid chemical or physical instabilities
• drugs with narrow therapeutic indices (cytotoxics, etc.)
• macromolecular recombinant biotech drugs, (signaling
proteins, monoclonal antibodies or fusion proteins)
• synthetic non-biological complexes (nanomedicines)
• drugs with short elimination half-lives and dosage intervals
not adjusted to the PN administration period
Admixing May be Possible
• stability documentation is sufficiently available
• no ingredients with potential incompatibilities (CAVE
polyvalent cations)
• large therapeutic index drugs (analgesics, sedatives,
H2-antagonists, etc.)
• simple stability testing is possible (pH, emulsion
characterization and visual inspection)
• well-established, often used, and physico–chemically fully
characterized small-molecular drugs
The following points should be considered as good practice using concomitant parenteral drug
therapy in PN patients [57,67]:
• Check if the medication is really needed.
• Ask for pharmaceutical advice, ideally from the nutrition support team when therapy regimen
are complicated or when drug admixing to PN admixture is considered.
• Admix compatible drugs to PN only just before administration in order to minimize interactions.
• Document procedure, creating a database to control and reference drug-PN admixing interventions.
• If possible collect samples for later analysis and evaluation.
• Use alternative infusion lines (inclusive of other catheter lumen) for drug administration whenever
possible. In absence of a separate line, intermittent intravenous drug administration in saline
or glucose solutions may be considered. Sufficient catheter rinsing before and after drug
administration is mandatory. Special attention is needed for metabolic adverse effects when
stopping PN administration because of intermittent drug administration. Insulin stimulation
induced by glucose infusion may for example be reduced by lowering the PN administration rates
over the last half hour before stopping.
10. Monitoring of Artificial Nutrition
Regular, defined and appropriate assessment may help to avoid respectively decrease the metabolic
complications of artificial nutrition. This should include the determination of (specific) individual
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nutrients, the monitoring and the course of the underlying disease and laboratory testing in addition
to the routine clinical assessment. Specific laboratory tests of artificial nutrition-associated parameters
include ([5–7]: Hematological testing, lipid status, liver and kidney function (especially in PN),
glucose, sodium, potassium, calcium, magnesium, phosphate, CRP, and iron status. Monitoring of
anthropometrics such as body weight, body mass index (BMI) and hydration status should as well be
performed to ensure the metabolic tolerance of artificial nutrition. Extended and frequent monitoring
is required at the initiation of PN for up to two months. Monitoring of long-term, clinically stable PN
patients is recommended every 3 to 6 months [6].
11. Home Artificial Nutrition
Some patients require a long-term artificial nutrition, if possible performed in a home setting when
no other hospital treatment is needed. The convenient and mostly nocturnal administration enables
patients to have a nearly “normal” everyday life and in many cases to keep on working. Patients
receiving home artificial nutrition show enhanced quality of life and better social integration [68].
Home artificial nutrition complications rates are lower than in hospital setting, possibly because of the
highly trained aseptic handling skills and to the more stable health patients’ situation [7]. Nevertheless,
it should undergo regular supervision by NSTs and a reliable reporting on critical incidences or health
problems has to be in place. European data show that home EN incidence is around 400 per million
and home PN incidence around 5 per million people per year. These differences are most likely due to
different healthcare systems and resources [3,5,68,69]. To draw conclusions how to better care these
home artificial nutrition patients, national registries are necessary to improve and to benchmark the
different national experiences [2].
12. Conclusions
The provision of artificial nutrition is a necessary when oral/enteral feeding is insufficient or
impossible. With the development of artificial nutrition, administration of EN and mainly PN
became convenient and safer, even possible in a home setting. Well-controlled procedures and steady
monitoring of the patients by an experienced NST are key issues in the successful management of
artificial nutrition, from the prescription (medical care) to through the validation (pharmaceutical care)
to the implementation (nursing care) of the therapy. Proper handling, compounding and concomitant
drug administration are of the highest relevance for therapeutic success and patient’s safety, in EN as
well as in PN therapy.
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